Half of health care industry executives surveyed last month think President Biden will take action against drug manufacturers that have stopped offering 340B pricing on their products. | Source: Advis

Half of Health Care Execs Surveyed Expect Biden to Act on Pharma’s 340B Pricing Denials

Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey of 2021. Advis posed the question amid headlines about drug manufacturers denying or placing conditions on 340B pricing on their products dispensed by contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.